Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis

被引:62
|
作者
Mirmosayyeb, Omid [1 ,2 ,3 ]
Brand, Serge [4 ,5 ,6 ,7 ,8 ]
Barzegar, Mahdi [1 ,3 ]
Afshari-Safavi, Alireza [9 ]
Nehzat, Nasim [1 ,10 ]
Shaygannejad, Vahid [1 ,3 ]
Bahmani, Dena Sadeghi [4 ,6 ,11 ]
机构
[1] Isfahan Univ Med Sci, Isfahan Neurosci Res Ctr, Esfahan 8174673461, Iran
[2] Univ Tehran Med Sci, Univ Sci Educ & Res Network USERN, Univ Council Epidemiol UCE, Tehran 1419733151, Iran
[3] Isfahan Univ Med Sci, Dept Neurol, Esfahan 8174673461, Iran
[4] Univ Basel, Psychiat Clin UPK, Ctr Depress Stress & Sleep Disorders, CH-4002 Basel, Switzerland
[5] Univ Basel, Dept Sport Exercise & Hlth, Div Sport Sci & Psychosocial Hlth, CH-4032 Basel, Switzerland
[6] Kermanshah Univ Med Sci KUMS, Hlth Inst, Subst Abuse Prevent Res Ctr, Kermanshah 6719851351, Iran
[7] Kermanshah Univ Med Sci KUMS, Hlth Inst, Sleep Disorders Res Ctr, Kermanshah 6719851351, Iran
[8] Univ Tehran Med Sci, Sch Med, Tehran 1416753955, Iran
[9] North Khorasan Univ Med Sci, Fac Hlth, Dept Biostat & Epidemiol, Bojnurd 7487794149, Iran
[10] Ahvaz Jundishapur Univ Med Sci, Fac Pharm, Ahvaz 6135715794, Iran
[11] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35209 USA
关键词
multiple sclerosis; age of onset; early onset; late onset; magnetic resonance imaging; predictors; EDSS score; relapsing-remitting MS; secondary progressive MS; NATURAL-HISTORY; THERAPEUTIC STRATEGIES; DIAGNOSTIC-CRITERIA; SLEEP DISTURBANCES; AGE; POPULATION; MRI; REMYELINATION; IMPAIRMENT; REVISIONS;
D O I
10.3390/jcm9051326
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Compared to the adult onset of multiple sclerosis (AOMS), both early-onset (EOMS) and late-onset (LOMS) are much less frequent, but are often under- or misdiagnosed. The aims of the present study were: 1. To compare demographic and clinical features of individuals with EOMS, AOMS and LOMS, and 2. To identify predictors for disability progression from relapsing remitting MS (RRMS) to secondary progressive MS (SPMS). Method: Data were taken from the Isfahan Hakim MS database. Cases were classified as EOMS (MS onset <= 18 years), LOMS (MS onset >50 years) and AOMS (MS >18 and <= 50 years). Patients' demographic and clinical (initial symptoms; course of disease; disease patterns from MRI; disease progress) information were gathered and assessed. Kaplan-Meier and Cox proportional hazard regressions were conducted to determine differences between the three groups in the time lapse in conversion from relapsing remitting MS to secondary progressive MS. Results: A total of 2627 MS cases were assessed; of these 127 were EOMS, 84 LOMS and 2416 AOMS. The mean age of those with EOMS was 14.5 years; key symptoms were visual impairments, brain stem dysfunction, sensory disturbances and motor dysfunctions. On average, 24.6 years after disease onset, 14.2% with relapsing remitting MS (RRMS) were diagnosed with secondary progressive MS (SPMS). The key predictor variable was a higher Expanded Disability Status Scale (EDSS) score at disease onset. Compared to individuals with AOMS and LOMS, those with EOMS more often had one or two relapses in the first two years, and more often gadolinium-enhancing brain lesions. For individuals with AOMS, mean age was 29.4 years; key symptoms were sensory disturbances, motor dysfunctions and visual impairments. On average, 20.5 years after disease onset, 15.6% with RRMS progressed to SPMS. The key predictors at disease onset were: a higher EDSS score, younger age, a shorter inter-attack interval and spinal lesions. Compared to individuals with EOMS and LOMS, individuals with AOMS more often had either no or three and more relapses in the first two years. For individuals with LOMS, mean age was 53.8 years; key symptoms were motor dysfunctions, sensory disturbances and visual impairments. On average, 14 years after disease onset, 25.3% with RRMS switched to an SPMS. The key predictors at disease onset were: occurrence of spinal lesions and spinal gadolinium-enhancement. Compared to individuals with EOMS and AOMS, individuals with LOMS more often had no relapses in the first two years, and higher EDSS scores at disease onset and at follow-up. Conclusion: Among a large sample of MS sufferers, cases with early onset and late onset are observable. Individuals with early, adult and late onset MS each display distinct features which should be taken in consideration in their treatment.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis
    Scalfari, Antonio
    Neuhaus, Anneke
    Daumer, Martin
    DeLuca, Gabriele C.
    Muraro, Paolo A.
    Ebers, George C.
    JAMA NEUROLOGY, 2013, 70 (02) : 214 - 222
  • [42] Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis
    Usta, Nuray Can
    Boz, Cavit
    Terzi, Murat
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2023, 224
  • [43] The Challenges of Treating Late-Onset Multiple Sclerosis
    Bourdette, Dennis
    Wooliscroft, Lindsey
    NEUROLOGY, 2024, 102 (06)
  • [44] The clinical features of late-onset multiple sclerosis in Greek patients
    Andreadou, E.
    Katirtzoglou, E.
    Evangelopoulos, M. E.
    Koutsis, G.
    Oikonomou, E.
    Dimitriou, A.
    Kilidireas, K.
    Vassilopoulos, D.
    JOURNAL OF NEUROLOGY, 2010, 257 : S77 - S77
  • [45] Effect of gender on late-onset multiple sclerosis
    Bove, Riley M.
    Healy, Brian
    Augustine, Ann
    Musallam, Alexander
    Gholipour, Taha
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (10) : 1472 - 1479
  • [46] Impaired remyelination in late-onset multiple sclerosis
    Stork, Lidia
    Stephan, Schirin
    Kutllovci, Adriane
    Brueck, Wolfgang
    Metz, Imke
    ACTA NEUROPATHOLOGICA, 2025, 149 (01)
  • [47] Senile (late-onset) type of multiple sclerosis
    Koutsouraki, E.
    Banaki, T.
    Hatzifilippou, E.
    Costa, V.
    Baloyannis, S. J.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S47 - S47
  • [48] Late-onset Multiple Sclerosis in Isfahan, Iran
    Etemadifar, Masoud
    Abtahi, Seyed-Hossein
    Minagar, Alireza
    Akbari, Mojtaba
    Masaeli, Ali
    Tabrizi, Nasim
    ARCHIVES OF IRANIAN MEDICINE, 2012, 15 (10) : 596 - 598
  • [49] Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient
    Marrodan, Mariano
    Laviano, Julia
    Oneto, Sofia
    Reino, Fabricio M.
    Delorme, Ricardo
    Fornillo, Florencia
    Fernandez, Jose
    Correale, Jorge
    NEUROLOGICAL SCIENCES, 2021, 42 (09) : 3893 - 3895
  • [50] Brain MRI in late-onset multiple sclerosis
    de Seze, J
    Delalande, S
    Michelin, E
    Gauvrit, JY
    Mackowiak, MA
    Ferriby, D
    Stojkovic, T
    Defebvre, L
    Pruvo, JP
    Vermersch, P
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (04) : 241 - 244